Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory — Boston, Massachusetts

Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory has participated in 1 clinical trials.

Therapeutic areas: Diabetes Type 2.

Sponsors: Beth Israel Deaconess Medical Center.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory?

Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory conducted?

Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory has 1 clinical trials on record. Their work covers Diabetes Type 2.

Is Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory accredited by Crixeo Health?

Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Beth Israel Deaconess Medical Center, Joslin Foot Center & Microcirculation Laboratory?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.